MA31435B1 - Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 - Google Patents
Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2Info
- Publication number
- MA31435B1 MA31435B1 MA32406A MA32406A MA31435B1 MA 31435 B1 MA31435 B1 MA 31435B1 MA 32406 A MA32406 A MA 32406A MA 32406 A MA32406 A MA 32406A MA 31435 B1 MA31435 B1 MA 31435B1
- Authority
- MA
- Morocco
- Prior art keywords
- norobillin
- antibody anti
- inhibitor
- malignant metastases
- malignant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La présente invention concerne des antagonistes de la nrp2, tels que des anticorps anti-nrp2 et leur utilisation dans la prévention et le traitement de métastases tumorales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/069179 WO2008143665A1 (fr) | 2007-05-17 | 2007-05-17 | Inhibition de métastases tumorales par des anticorps anti-neuropiline 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31435B1 true MA31435B1 (fr) | 2010-06-01 |
Family
ID=39301228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32406A MA31435B1 (fr) | 2007-05-17 | 2009-12-07 | Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 |
Country Status (17)
Country | Link |
---|---|
US (2) | US8648173B2 (fr) |
EP (1) | EP2152307B1 (fr) |
JP (1) | JP5745840B2 (fr) |
KR (1) | KR101520115B1 (fr) |
CN (1) | CN101754771B (fr) |
AU (1) | AU2007353778B9 (fr) |
BR (1) | BRPI0721660A2 (fr) |
CA (1) | CA2687247A1 (fr) |
CR (1) | CR11126A (fr) |
ES (1) | ES2469743T3 (fr) |
HK (2) | HK1134040A1 (fr) |
IL (1) | IL202005A (fr) |
MA (1) | MA31435B1 (fr) |
MX (1) | MX2009012421A (fr) |
NO (1) | NO20093542L (fr) |
UA (1) | UA99292C2 (fr) |
WO (1) | WO2008143665A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008251381B2 (en) * | 2007-05-11 | 2014-10-30 | The Johns Hopkins University | Biomarkers for melanoma |
JP2013507641A (ja) * | 2009-10-13 | 2013-03-04 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 黒色腫腫瘍細胞の識別のためのバイオマーカー |
DK2970921T3 (en) | 2013-03-15 | 2019-01-14 | Atyr Pharma Inc | Histidyl-tRNA synthetase-Fc conjugates |
WO2015095686A1 (fr) * | 2013-12-20 | 2015-06-25 | Trustees Of Boston University | Analyses et méthodes associées au traitement de mélanomes |
CA3060514A1 (fr) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions et procedes pour le traitement d'inflammation pulmonaire |
WO2018226671A1 (fr) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1 |
CN113226367A (zh) * | 2018-04-06 | 2021-08-06 | Atyr 医药公司 | 包括抗nrp2抗体的组合物和方法 |
JP2022551603A (ja) * | 2019-10-03 | 2022-12-12 | エータイアー ファーマ, インコーポレイテッド | 抗nrp2抗体を含む組成物および方法 |
CN114277152A (zh) * | 2022-01-14 | 2022-04-05 | 张赟建 | 用于预测甲状腺乳头状癌淋巴结转移的特异性基因及制备方法 |
CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
NZ500077A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized antibodies to vascular endothelial growth factor (VEGF) and methods for their preparation. |
BRPI9809387B8 (pt) | 1997-04-07 | 2021-05-25 | Genentech Inc | anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende |
CA2313607A1 (fr) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Fonction et utilisation de l'antagoniste du recepteur de la neuropiline |
EP1037981A1 (fr) | 1997-12-09 | 2000-09-27 | Children's Medical Center Corporation | Inhibiteurs solubles du facteur de croissance de l'endothelium vasculaire et leurs utilisations |
US6417169B1 (en) * | 1998-04-23 | 2002-07-09 | Genesense Technologies Inc. | Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth |
US20030113324A1 (en) | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
EP1513879B1 (fr) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Bibliotheques de phages et anticorps synthetiques |
WO2005030240A2 (fr) | 2003-09-23 | 2005-04-07 | Ludwig Institute For Cancer Research | Produits vegf-c ou vegf-d et methodes de stimulation des cellules souches neurales |
EP1439192A1 (fr) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Inhibiteurs de neuropilin-1 |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
-
2007
- 2007-05-17 UA UAA200913144A patent/UA99292C2/uk unknown
- 2007-05-17 KR KR1020097026228A patent/KR101520115B1/ko not_active IP Right Cessation
- 2007-05-17 ES ES07783895.1T patent/ES2469743T3/es active Active
- 2007-05-17 JP JP2010508352A patent/JP5745840B2/ja not_active Expired - Fee Related
- 2007-05-17 EP EP07783895.1A patent/EP2152307B1/fr active Active
- 2007-05-17 US US12/598,537 patent/US8648173B2/en not_active Expired - Fee Related
- 2007-05-17 BR BRPI0721660-2A patent/BRPI0721660A2/pt not_active IP Right Cessation
- 2007-05-17 MX MX2009012421A patent/MX2009012421A/es active IP Right Grant
- 2007-05-17 AU AU2007353778A patent/AU2007353778B9/en not_active Ceased
- 2007-05-17 CA CA002687247A patent/CA2687247A1/fr not_active Abandoned
- 2007-05-17 WO PCT/US2007/069179 patent/WO2008143665A1/fr active Application Filing
- 2007-05-17 CN CN200780053792.7A patent/CN101754771B/zh not_active Expired - Fee Related
-
2009
- 2009-11-09 IL IL202005A patent/IL202005A/en not_active IP Right Cessation
- 2009-11-24 CR CR11126A patent/CR11126A/es not_active Application Discontinuation
- 2009-12-07 MA MA32406A patent/MA31435B1/fr unknown
- 2009-12-16 NO NO20093542A patent/NO20093542L/no not_active Application Discontinuation
-
2010
- 2010-03-01 HK HK10102110.9A patent/HK1134040A1/xx not_active IP Right Cessation
- 2010-11-30 HK HK10111154.7A patent/HK1144556A1/xx not_active IP Right Cessation
-
2013
- 2013-06-11 US US13/915,363 patent/US8920805B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CR11126A (es) | 2010-05-19 |
ES2469743T3 (es) | 2014-06-18 |
HK1134040A1 (en) | 2010-04-16 |
BRPI0721660A2 (pt) | 2013-01-22 |
CA2687247A1 (fr) | 2008-11-27 |
JP2010527350A (ja) | 2010-08-12 |
CN101754771B (zh) | 2015-03-04 |
CN101754771A (zh) | 2010-06-23 |
EP2152307B1 (fr) | 2014-04-16 |
KR101520115B1 (ko) | 2015-05-13 |
HK1144556A1 (en) | 2011-02-25 |
AU2007353778B2 (en) | 2013-11-07 |
IL202005A (en) | 2014-11-30 |
IL202005A0 (en) | 2010-06-16 |
AU2007353778A1 (en) | 2008-11-27 |
WO2008143665A1 (fr) | 2008-11-27 |
MX2009012421A (es) | 2009-12-01 |
US8648173B2 (en) | 2014-02-11 |
US8920805B2 (en) | 2014-12-30 |
US20140234312A1 (en) | 2014-08-21 |
KR20100018567A (ko) | 2010-02-17 |
NO20093542L (no) | 2010-02-12 |
AU2007353778B9 (en) | 2014-04-03 |
EP2152307A1 (fr) | 2010-02-17 |
JP5745840B2 (ja) | 2015-07-08 |
US20100172921A1 (en) | 2010-07-08 |
UA99292C2 (uk) | 2012-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31435B1 (fr) | Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 | |
MA33256B1 (fr) | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
MA34818B1 (fr) | Anticorps anti-pcsk9 et procédés d'utilisation | |
MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
MA30384B1 (fr) | Therapies combinatoires | |
MA34780B1 (fr) | Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation | |
CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
NO20081636L (no) | FAP - inhibitorer | |
MA33492B1 (fr) | Inhibiteurs de bace | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
MA31167B1 (fr) | Inhibiteurs de l'activite de akt | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
SG155163A1 (en) | Pharmacokinetically improved compounds | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
EA201300246A1 (ru) | Ингибиторы тирозинкиназы брутона | |
MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
CO6571886A2 (es) | Antagonistas de pcsk9 | |
MA34753B1 (fr) | Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes | |
MA38176A1 (fr) | Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a | |
MA31977B1 (fr) | Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci |